Vericel Reports 2Q16 Orthobiologic Revenue
Vericel (VCEL) posted 2Q16 Carticel revenue of US $9.0MM, -1.1% vs. 2Q15, as reported. Carticel is an autologous chondrocyte implant marketed in the U.S. for the treatment of knee cartilage defects.
An anticipated downtime for Carticel's cleanrooms, due to the replacement of a rooftop air handler, resulted in an ~16% reduction in product shipment dates in 2Q. The cleanrooms were validated and back online in accordance with timelines, and leadership noted the hightest level of Caricel implants in June in the past four years.
During 2Q, VCEL entered into a collaboration with Dohmen Life Science, a provider of patient and reimbursement services for specialty biologics. Dohmen will provide patient support services and payor contracting/product reimbursement for Carticel and also for the MACI Autologous Cultured Chondrocyte implant, if approved, under a fee-per-service structure.
This is a transition from the previous exclusive distributor structure that was inherited with the acquisition of Carticel.
Sources: Vericel Corporation, ORTHOWORLD Inc.